Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Grants Pressure Bio Extension to Regain Compliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences today said that it has received notification from Nasdaq that the firm has been granted an extension until Oct. 3, 2011, to regain compliance with the exchange's minimum stockholders' equity requirement of $2.5 million.

The South Easton, Mass.-based firm received the staff deficiency letter from Nasdaq in early April saying that it was not incompliance with the rule. It submitted a written plan to Nasdaq on May 23, outlining its strategy to regain compliance. In that plan, Pressure Bio said that it would need to raise at least $5 million in additional equity capital to report stockholders' equity of more than $2.5 million.

Nasdaq notified the firm on June 10 that it has until Oct. 3, 2011, to regain compliance.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.